Prolonged Influenza Virus Shedding and Emergence of Antiviral Resistance in Immunocompromised Patients and Ferrets e1003343

• Published in: PLoS pathogens Vol. 9; no. 5
• Main Authors: Vries, Erhard vander, Stittelaar, Koert J, Amerongen, Geert van, Kroeze, J BVeldhuis, Waal, Leon de, Fraaij, Pieter LA, Meesters, Roland J, Luider, Theo M, Nagel, Bart vander, Koch, Birgit, Vulto, Arnold G, Schutten, Martin, Osterhaus, D ME
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 01.05.2013
• Subjects: Animals; Hospitalization; Infections; Influenza A virus; Medical research; Mortality; Mustela; Patients; Swine flu; Viruses
• ISSN: 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1003343

Immunocompromised individuals tend to suffer from influenza longer with more serious complications than otherwise healthy patients. Little is known about the impact of prolonged infection and the efficacy of antiviral therapy in these patients. Among all 189 influenza A virus infected immunocompromised patients admitted to ErasmusMC, 71 were hospitalized, since the start of the 2009 H1N1 pandemic. We identified 11 (15%) cases with prolonged 2009 pandemic virus replication (longer than 14 days), despite antiviral therapy. In 5 out of these 11 (45%) cases oseltamivir resistant H275Y viruses emerged. Given the inherent difficulties in studying antiviral efficacy in immunocompromised patients, we have infected immunocompromised ferrets with either wild-type, or oseltamivir-resistant (H275Y) 2009 pandemic virus. All ferrets showed prolonged virus shedding. In wild-type virus infected animals treated with oseltamivir, H275Y resistant variants emerged within a week after infection. Unexpectedly, oseltamivir therapy still proved to be partially protective in animals infected with resistant virus. Immunocompromised ferrets offer an attractive alternative to study efficacy of novel antiviral therapies.